Bioretec’s initial public offering and listing on Nasdaq First North has been cancelled
Bioretec Ltd's Board of Directors has on 17 June 2021 decided to cancel the initial public offering announced on 4 June 2021. The Board of Directors has also decided to cancel the listing of the Company's shares on Nasdaq First North Growth Market Finland maintained by Nasdaq Helsinki Ltd.
Bioretec wishes to thank all the investors who took part in the offering for their interest and trust in the company.
Bioretec in brief
Bioretec Ltd is a medical device company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The company develops, manufactures and commercializes innovative bioresorbable orthopedic implants and materials for bone and soft tissue injuries. Bioretec's products are used in approximately 40 countries, and the company continues to further research and develop materials and products for load-bearing clinical applications. Based in Tampere, Finland, Bioretec employs 24 dedicated professionals, supported by a top class Scientific Advisory Board with internationally recognized top-class surgeons as members.
Materials
- Offering circular (PDF)
- Interim report (PDF)
- Financial Statements (PDF)
- Auditor´s report (PDF)
- Articles of Association (PDF)
Releases
- 17/6/2021 Bioretec cancels its initial public offering and listing
- 7/6/2021 Bioretec has applied for its shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering
- 4/6/2021 Bioretec announces the subscription price and publishes a prospectus for its contemplated IPO and listing on Nasdaq First North Growth Market Finland
- 2/6/2021 Bioretec intends to launch an initial public offering and listing on Nasdaq First North Growth Market Finland